EL Stock Recent News
EL LATEST HEADLINES
Estee Lauder (EL) concluded the recent trading session at $148.98, signifying a +1.06% move from its prior day's close.
Estee Lauder (EL) is on track to operationalize the Profit Recovery Plan to focus on rebuilding stronger and more sustainable profitability alongside supporting sales growth.
Estée Lauder Companies, Inc. NYSE: EL is among an increasingly smaller group of stocks that have yet to mount a serious comeback to recent selloffs. Having gained more than 200% from January 2019 through January 2022, investors in the cosmetics giant then gained a harsh lesson in gravity.
The shares of Estee Lauder Companies Inc (NYSE:EL) are 0.9% higher to trade at $153.41 this morning, after Citi upgraded the luxury retailer to to "buy" from "neutral.
Estee Lauder Cos. (EL) shares jumped Thursday after Bank of America Securities (BofA) analysts upgraded the stock and raised their price target for it, saying they see “meaningful growth” ahead for the beauty products maker.
Estee Lauder Companies Inc (NYSE:EL, ETR:ELAA)'s expected rebound has prompted analysts at the Bank of America to upgrade their rating and boost their price target on the New York-headquartered cosmetics company. Describing the stock as a “Cinderella Story,” the analysts have upped their rating on the stock from ‘Neutral' to ‘Buy' and price target from $160 to $170.
Estee Lauder (EL) is expanding its omnichannel capabilities to aid flexible and convenient shopping options for consumers. Management is on track to operationalize the Profit Recovery Plan.
The Investment Committee share their top stocks for the second half.
Estée Lauder (NYSE: EL) reported upbeat Q2'24 results last month (the fiscal year ends in June). The company's revenues stood at $4.3 billion and earnings came in at $0.88, well above the consensus estimates of $4.2 billion, and $0.34, respectively.
High levels of cancer-causing chemical benzene were detected in some acne treatments from brands including Estee Lauder‘s Clinique, Target‘s Up & Up, and Reckitt Benckiser-owned Clearasil, said independent U.S. laboratory Valisure.